Please login to the form below

Not currently logged in
Email:
Password:

darunavir-STR

This page shows the latest darunavir-STR news and features for those working in and with pharma, biotech and healthcare.

Janssen’s single tablet Symtuza gains NHS England funding 

Janssen’s single tablet Symtuza gains NHS England funding 

Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide [D/C/F/TAF]).is once-daily darunavir-based single tablet regimen (STR), for the treatment of HIV-1 infection in adults and adolescents aged ... 2014. “We are delighted that NHSE has

Latest news

  • Positive trial results for Janssen’s Symtuza boosts its HIV credentials Positive trial results for Janssen’s Symtuza boosts its HIV credentials

    The STR provided ‘effective’ and ‘durable’ viral suppression. Janssen’s darunavir-based single tablet regimen (STR) Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) showed a positive outcome in the treatment of HIV

  • Janssen wins European approval for Symtuza Janssen wins European approval for Symtuza

    European Commission approves the drug to treat HIV-1. The European Commission (EC) has approved Janssen’s Symtuza (darunavir-STR) to treat adults with human immunodeficiency virus type 1 (HIV-1). ... Dr Frank Wiegand, medical director, Janssen UK, said:

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....
Could formulary intelligence be your brand differentiator?
Proprietary research, and the COVID-19 experience, shows how formulary intelligence can drive competitive advantage at launch...

Infographics